Pancreatic ß-Cell Responsiveness during Meal Tolerance Test: Model Assessment in Normal Subjects and Subjects with Newly Diagnosed Noninsulin-Dependent Diabetes Mellitus1
Roman Hovorka,
Ludovic Chassin,
Stephen D. Luzio,
Rebecca Playle and
David R. Owens
Metabolic Modelling Group, Center for Measurement and Information
in Medicine, City University (R.H., L.C.), London, United Kingdom EC1V
OHB; the Diabetes Research Unit, University of Wales College of
Medicine, Academic Center, Llandough Hospital and Community National
Health Service Trust (S.D.L., R.P., D.R.O.), Penarth, South Glamorgan,
United Kingdom CF64 2XX
Address all correspondence and requests for reprints to: Dr. Roman Hovorka, Metabolic Modelling Group, Center for Measurement and Information in Medicine, City University, Northampton Square, London, United Kingdom EC1V OHB. E-mail: r.hovorka{at}city.ac.uk
A model-based method was developed to quantify pancreatic
ß-cellresponsiveness during a meal tolerance test (MTT). C peptide
secretionwas related in a linear fashion to glucose concentration,
whereasthe standard population model was used to derive transfer rate
constantsof the two compartmental model of C peptide kinetics. Two
indexesof pancreatic ß-cell responsiveness were defined: 1)
postprandialsensitivity MI (ability of postprandial
glucose to stimulateß-cell), and 2) basal sensitivity M0
(ability of fastingglucose to stimulate ß-cell). The method was
evaluatedusing plasma glucose and C peptide measured over 180 min with
a10- to 30-min sampling interval during a MTT (75 g carbohydrates;500
Cal) performed in 16 normal subjects (7 men and 9 women;age, 50
± 10 yr; body mass index, 29.2 ± 3.6 kg/m2;fasting
plasma glucose, 5.1 ± 0.5 mmol/L; mean ±SD)
and 16 body mass index-matched subjects with newly diagnosed
noninsulin-dependentdiabetes mellitus (NIDDM; 15 men and 1 woman; age,
50 ±9 yr; body mass index, 29.3 ± 3.7 kg/m2;
fasting plasmaglucose, 12.6 ± 3.2 mmol/L). MI and
M0 indexes were estimatedwith very good precision
(coefficient of variation, <15%).Subjects with NIDDM demonstrated
lower postprandial sensitivityMI (17.7 ± 11.4
vs. 90.0 ± 43.3 x 10-9/min;
NIDDMvs. normal, P < 0.001) and
basal sensitivity M0 (5.4 ±2.2 vs.
10.3 ± 4.9 x 10-9/min; P
< 0.005). Deconvolutionanalysis documented that the relationship
between C peptidesecretion and glucose concentration is approximately
linearduring MTT in both normal subjects (plasma glucose range, 58
mmol/L)and subjects with NIDDM (1217 mmol/L). We conclude that
pancreaticresponsiveness during glucose stimulation (MI)
and under basalconditions (M0) can be obtained from this
novel method duringMTT in healthy and disease states.
This article has been cited by other articles:
K.-D. Kohnert, P. Augstein, E. Zander, P. Heinke, K. Peterson, E.-J. Freyse, R. Hovorka, and E. Salzsieder Glycemic Variability Correlates Strongly With Postprandial{beta}-Cell Dysfunction in a Segment of Type 2 Diabetic Patients Using Oral Hypoglycemic Agents
Diabetes Care,
June 1, 2009;
32(6):
1058 - 1062.
[Abstract][Full Text][PDF]
R. Hovorka, H. Jayatillake, E. Rogatsky, V. Tomuta, T. Hovorka, and D. T. Stein Calculating glucose fluxes during meal tolerance test: a new computational approach
Am J Physiol Endocrinol Metab,
August 1, 2007;
293(2):
E610 - E619.
[Abstract][Full Text][PDF]
M. Campioni, G. Toffolo, L. T. Shuster, F. J. Service, R. A. Rizza, and C. Cobelli Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study
Am J Physiol Endocrinol Metab,
January 1, 2007;
292(1):
E54 - E60.
[Abstract][Full Text][PDF]
W. S. Shim, S. K. Kim, H. J. Kim, E. S. Kang, C. W. Ahn, S. K. Lim, H. C. Lee, and B. S. Cha Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes.
Eur. J. Endocrinol.,
October 1, 2006;
155(4):
615 - 622.
[Abstract][Full Text][PDF]
A. E. Panteleon, M. Loutseiko, G. M. Steil, and K. Rebrin Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system.
Diabetes,
July 1, 2006;
55(7):
1995 - 2000.
[Abstract][Full Text][PDF]
S. Camastra, M. Manco, A. Mari, S. Baldi, A. Gastaldelli, A. V. Greco, G. Mingrone, and E. Ferrannini {beta}-Cell Function in Morbidly Obese Subjects During Free Living: Long-Term Effects of Weight Loss
Diabetes,
August 1, 2005;
54(8):
2382 - 2389.
[Abstract][Full Text][PDF]
A. Caumo and L. Luzi First-phase insulin secretion: does it exist in real life? Considerations on shape and function
Am J Physiol Endocrinol Metab,
September 1, 2004;
287(3):
E371 - E385.
[Abstract][Full Text][PDF]
G. M. Steil, C.-m. Hwu, R. Janowski, F. Hariri, S. Jinagouda, C. Darwin, S. Tadros, K. Rebrin, and M. F. Saad Evaluation of Insulin Sensitivity and {beta}-Cell Function Indexes Obtained From Minimal Model Analysis of a Meal Tolerance Test
Diabetes,
May 1, 2004;
53(5):
1201 - 1207.
[Abstract][Full Text][PDF]
A. Mari, O. Schmitz, A. Gastaldelli, T. Oestergaard, B. Nyholm, and E. Ferrannini Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects
Am J Physiol Endocrinol Metab,
December 1, 2002;
283(6):
E1159 - E1166.
[Abstract][Full Text][PDF]
A. Mari, A. Tura, A. Gastaldelli, and E. Ferrannini Assessing Insulin Secretion by Modeling in Multiple-Meal Tests: Role of Potentiation
Diabetes,
February 1, 2002;
51(90001):
S221 - 226.
[Abstract][Full Text][PDF]
E. Breda, G. Toffolo, K. S. Polonsky, and C. Cobelli Insulin Release in Impaired Glucose Tolerance: Oral Minimal Model Predicts Normal Sensitivity to Glucose but Defective Response Times
Diabetes,
February 1, 2002;
51(90001):
S227 - 233.
[Abstract][Full Text][PDF]
A. I. Albarrak, S. D. Luzio, L. J. Chassin, R. A. Playle, D. R. Owens, and R. Hovorka Associations of Glucose Control with Insulin Sensitivity and Pancreatic {beta}-Cell Responsiveness in Newly Presenting Type 2 Diabetes
J. Clin. Endocrinol. Metab.,
January 1, 2002;
87(1):
198 - 203.
[Abstract][Full Text][PDF]
S. D. Luzio, D. M. Anderson, and D. R. Owens Effects of Timing of Administration and Meal Composition on the Pharmacokinetic and Pharmacodynamic Characteristics of the Short-Acting Oral Hypoglycemic Agent Nateglinide in Healthy Subjects
J. Clin. Endocrinol. Metab.,
October 1, 2001;
86(10):
4874 - 4880.
[Abstract][Full Text][PDF]
E. Breda, M. K. Cavaghan, G. Toffolo, K. S. Polonsky, and C. Cobelli Oral Glucose Tolerance Test Minimal Model Indexes of {beta}-Cell Function and Insulin Sensitivity
Diabetes,
January 1, 2001;
50(1):
150 - 158.
[Abstract][Full Text]